Pharmaceuticals India

India Diabetes Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

India Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.17 Bn Placeholder estimate
Estimate 2025 $1.28 Bn 1.6% of the global market
Projected 2034 $3.02 Bn 135.8% Adds $1.74 Bn over 9 forecast years
CAGR 2025–2034 10.0% Faster than 38% of 183 Pharmaceuticals markets here
Key players 6 +1
  • India is 1.65% of the global market.
  • In APAC, the largest is China at $6.39 Bn.
  • Fastest growing: India (this report) at 10% a year.
  • India ranks 4th of 14 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.74 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Drugs Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.17 Bn — —
2025 (base) $1.28 Bn +$116.6 Mn —
2026 (forecast) $1.41 Bn +$128.2 Mn +10%
2027 (forecast) $1.55 Bn +$141.0 Mn +21%
2028 (forecast) $1.71 Bn +$155.1 Mn +33.1%
2029 (forecast) $1.88 Bn +$170.6 Mn +46.4%
2030 (forecast) $2.06 Bn +$187.7 Mn +61.1%
2031 (forecast) $2.27 Bn +$206.5 Mn +77.2%
2032 (forecast) $2.50 Bn +$227.1 Mn +94.9%
2033 (forecast) $2.75 Bn +$249.8 Mn +114.4%
2034 (forecast) $3.02 Bn +$274.8 Mn +135.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Diabetes Drugs Market Analysis at a glance
Market size, 2025$1.28 Bn placeholder estimate
Forecast, 2034$3.02 Bn placeholder estimate
Growth (CAGR), 2025–203410.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
Active clinical trials52 in IndiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 21 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Diabetes Drugs Market Analysis Executive Summary

Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.

Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).

Bar chart: India Diabetes Drugs market size, 2024–2034, placeholder estimates. $1.17 Bn in 2024, $1.28 Bn in 2025 and $3.02 Bn in 2034, 10.0% CAGR.
India Diabetes Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Diabetes Drugs Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.

Competitive Landscape for Diabetes Drugs Market in India

The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Drugs Market in India

Diabetes Drugs in India: rules, payment and research

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2] ClinicalTrials.gov lists 52 studies on Diabetes Drugs that are recruiting, active or about to start in India.⁠[3] Diabetes (ages 20–79): 10.5% of people 20–79 in 2024, the latest World Bank figure for India.⁠[4]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 21 Nov 2026.

[4] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Drugs in context

India compared

  • Diabetes (ages 20–79): 10.5% of people 20–79 (2024). World: 10.8% of people 20–79 (2024). 8th highest of the 18 countries we cover in APAC.[1]
  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 12th highest of the 17 countries we cover in APAC.[2]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 13th highest of the 17 countries we cover in APAC.[3]

[1] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Drugs market in India?
Placeholder estimate: about $1.28 Bn in 2025, rising to about $3.02 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Drugs market in India growing?
Placeholder estimate: about 10.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Drugs market report cover?
The report splits the market by drug class (Insulin, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors and more), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Diabetes Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and Boehringer Ingelheim GmbH.
What is driving the Diabetes Drugs market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
Who regulates Diabetes Drugs in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How many clinical trials on Diabetes Drugs are running in India?
52 studies are recruiting, active or about to start in India, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 21 Nov 2026.
What does World Bank report for India?
Diabetes (ages 20–79): 10.5% of people 20–79 in 2024, the latest World Bank figure. Source: World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 21 Nov 2026.
How many people in India are 65 or older?
7.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on diabetes

See the topic